Objective-Protein Kinase C delta (PKC␦) is expressed in platelets and activated downstream of protease-activated receptors (PAR)s and glycoprotein VI (GPVI) receptors. The purpose of this study was to investigate the role of PKC␦ in platelets. Methods and Results-We evaluated the role of PKC␦ in platelets using two approaches-pharmacological and molecular genetic approach. In human platelets pretreated with isoform selective antagonistic RACK peptide (␦ V1-1)TAT, and in the murine platelets lacking PKC␦, PAR4-mediated dense granule secretion was inhibited, whereas GPVI-mediated dense granule secretion was potentiated. These effects were statistically significant in the absence and presence of thromboxane A 2 (TXA 2 ). Furthermore, TXA 2 generation was differentially regulated by PKC␦. However, PKC␦ had a small effect on platelet P-selectin expression. Calcium-and PKC-dependent pathways independently activate fibrinogen receptor in platelets. When calcium pathways are blocked by dimethyl-BAPTA, AYPGKF-induced aggregation in PKC␦ null mouse platelets and in human platelets pretreated with (␦ V1-1)TAT, was inhibited. In a FeCl 3 -induced injury in vivo thrombosis model, PKC␦ Ϫ/Ϫ mice occluded similar to their wild-type littermates. Conclusions-Hence, we conclude that PKC␦ differentially regulates platelet functional responses such as dense granule secretion and TXA 2 generation downstream of PARs and GPVI receptors, but PKC␦ deficiency does not affect the thrombus formation in vivo. (Arterioscler Thromb Vasc Biol. 2009;29:699-705.) 
P rotein kinase Cs (PKCs) are members of the extended AGC (Protein Kinase A, G, and C) family of differentially expressed serine/threonine kinases implicated in a diverse array of cellular functions. 1, 2 After activation, these kinases migrate to different subcellular locations including the plasma membrane and cytoskeletal elements where they regulate different physiological functions. 3 PKC isoforms are subdivided into 3 groups based on their lipid and cofactor requirements: the diacylglycerol (DAG) and calciumsensitive conventional isoforms (␣, ␤I, ␤II, and ␥), the DAG-sensitive and calcium-insensitive novel isoforms (␦, , , and ), and the phosphatidylinositide trisphosphatesensitive atypical isoforms (, , , and ). 4 Intrinsic function of PKCs is regulated by 3 mechanisms: (1) binding of the cofactor that allosterically activates the enzyme, (2) phosphorylation on the activation loop residue that primes the enzyme for catalysis, and (3) interaction with proteins that position it close to its regulators and substrates. 1 RACKs (Receptors for activated C-Kinase) bind to individual PKC isozymes after their activation and translocate them to their target substrates. Each PKC has a unique RACK that regulates the positioning of the PKC in close proximity to their target substrates. 5 The PKCs then phosphorylate their substrates and mediate downstream signaling events. 6, 7 Modulation of PKC translocation and function has been disrupted using the inhibitor in various cells, organs, and animals. 8, 9 (␦ V1-1)TAT, which is an anti-PKC␦ RACK peptide conjugated to a TAT carrier, binds to the RACK binding region on PKC␦. This prevents the binding of endogenous RACK to PKC␦. By using (␦ V1-1)TAT in human platelets, we demonstrated the role of PKC␦ in regulating platelet functional responses. To substantiate the findings from the pharmacological inhibition, we performed similar experiments in murine platelets isolated from PKC␦ Ϫ/Ϫ and their agematched PKC␦ ϩ/ϩ wild-type littermates.
Platelet granule secretion is one of the early events of platelet functional responses. Platelet dense granules contain ADP, ATP, Ca 2ϩ , and serotonin that amplify platelet responses by acting on their respective receptors. 35 Alphagranules, on the other hand, contain homologs of plasma proteins and platelet-specific proteins. 10 One of the components of ␣-granules is P-selectin, which is expressed on the surface of activated platelets and aids in platelet-leukocyte interaction. 11 After platelet secretion, TXA 2 is generated which diffuses across the platelet membrane and recruits more platelets to the site of injury. Activation of platelets by physiological agonists such as thrombin and collagen result in the generation of thromboxane. At low doses of agonist, secretion is dependent on TXA 2 generation and thus further amplification of platelet functional responses ensue. These events result in the formation of platelet plug. Inside-out signaling results in the activation of fibrinogen receptor ␣ IIb ␤ 3 . There are 2 pathways by which the fibrinogen receptor can be activated, a Ca 2ϩ -dependent pathway and a PKC-dependent pathway. 12 However, the specific PKC isoforms that can cause activation of ␣ IIb ␤ 3 in the absence of Ca 2ϩ has not been investigated yet.
Protein Kinase Cs have been implicated in platelet secretion. 13 Of the novel isoforms, PKC␦ is implicated in inhibition of cell growth, cell differentiation, apoptosis, and tumor suppression in immune cells. 14 PKC␦ is activated by strong agonists such as thrombin and collagen, but not by ADP. 15 Activated PKC␦ positively regulates PAR-mediated dense granule secretion and negatively regulates GPVI-mediated dense granule secretion. 15, 16 These studies used rottlerin, an inhibitor of PKC␦ at IC 50 of 3 to 6 mol/L. 17 However, recent reports have raised concerns regarding the specificity of rottlerin. 18 -22 In this study, by combining the pharmacological approaches with the use of platelets from PKC␦ knockout mice, we investigated the role of PKC␦ in platelet functional responses. We show that PKC␦ differentially regulates PAR and GPVI-mediated dense granule secretion and TXA 2 generation. These effects translate into faster time to occlusion leading to thrombus formation in vivo.
Materials and Methods
Approval for this study was obtained from the Institutional Review Board of Temple University (Philadelphia, Pa), and mice were used for physiological measurements using the protocol approved by the Institutional Animal Care and Use Committee (IACUC).
Materials
Convulxin, fibrinogen (Fraction I, type I), apyrase grade VII, thrombin, and acetylsalicylic acid were obtained from Sigma. Luciferin-luciferase reagent was purchased from Chrono-Log. Antiphospho and anti-PKC␦ antibodies were obtained Santa Cruz Biotechnology Inc. The acetoxymethyl ester of the calcium chelator 5,5Ј-dimethyl-bis-(o-aminophenoxy)ethane-N,N,NЈ,NЈtetra-acetic acid (dimethyl BAPTA) was purchased from NEN. All the other reagents were of reagent grade, and deionized water was used throughout.
Animals
PKC␦ Ϫ/Ϫ (C57BL/6 background) mice and their age-matched wildtype littermates were used. These mice were obtained from Dr Keiko Nakayama (Tohoku Graduate School of Medicine, Japan). All the mice obtained from the source were transferred to the Central Animal Facility (CAF) under the head and director of the CAF in Temple University School of Medicine.
Preparation of Washed Human and Murine Platelets
The platelets were isolated from humans and mice according to previously established protocol. 23
Measurement of Platelet Dense Granule Secretion in Human and Mouse Platelets
ATP secretion from platelet dense granules was determined in aspirin-treated human platelets or indomethacin-treated mouse platelets by using the Luciferin-Luciferase assay. The platelets were treated with aspirin (1 mmol/L) or indomethacin (10 mol/L) for 1 minute and then stimulated with agonists in a lumi-aggregometer at 37°C with stirring at 900 rpm, and the corresponding luminescence was measured.
Measurement of Platelet ␣-Granule Secretion in Murine Platelets
P-selectin (CD62) expression on platelets from PKC␦ Ϫ/Ϫ murine platelets and those from wild-type littermates was measured according to a established protocol using FITC-labeled anti-CD62 antibody (Becton Dickinson). 24
Measurement of thromboxane A 2 Generation
Washed murine platelets without indomethacin treatment were stimulated in a platelet aggregometer, and levels of TXB 2 were determined according to established protocol. 25 
In Vivo Thrombosis Model
Adult mice (6 to 8 weeks old, weight Ϸ25 gms) were anesthetized by intraperitoneal injection of pentobarbital (40 mg/kg). Experimental groups consisted of PKC␦ ϩ/ϩ and PKC␦ Ϫ/Ϫ mice (nϭ11). The mice were subjected to thrombosis according to a established protocol. 24 The operator was blinded to mouse genotype while performing all experiments.
Statistical Analysis
The results were quantitated, expressed as meanϮSD. The data were statistically analyzed using Student t test and PՅ0.05 was considered significant.
Results

PKC␦ Differentially Regulates PARs and GPVI-Mediated Dense Granule Secretion in Human Platelets
Previous studies from our laboratory and others have shown that PKC␦ is important for PAR-mediated dense granule release, but it negatively regulates GPVI-mediated secretion. 15 However, as these studies used a nonselective inhibitor rottlerin, we investigated the role of PKC␦ using more selective tools to block this isoform. First, we used (␦ V1-1)TAT (1 mol/L), an anti-PKC␦ RACK peptide, which specifically blocks translocation of PKC␦ to its target substrate. 9, 26 When human platelets were preincubated for 15 minutes with (␦ V1-1)TAT (1 mol/L), 200 mol/L AYPGKF-induced dense granule release in aspirin-treated human platelets was inhibited ( Figure 1A ). However, when the platelets were treated with a control peptide, there was no effect on AYPGKF-induced secretion ( Figure 1A ) and these were statistically significant (PϽ0.05). Similar experiments were performed by stimulating platelets with 60 ng/mL convulxin, a GPVI agonist. Contrarily, convulxin-induced dense granule release was potentiated by the pretreatment of platelets for 15 minutes with PKC␦ specific antagonistic RACK peptide ( Figure 1B) . However, the control peptide did not affect the GPVI-mediated secretion ( Figure 1B) . The potentiation of convulxin-induced ATP secretion by (␦ V1-1)TAT was also statistically significant ( Figure 1B) . These results indicate that PKC␦ positively regulates PARmediated dense granule secretion, whereas it negatively regulates GPVI-mediated dense granule secretion.
Regulation of Dense Granule Secretion in PKC␦ Null Murine Platelets
As the specificity of the pharmacological agents might be argued, we used platelets from mice lacking PKC␦ isoform. PKC␦ knock out mice were generated by 2 groups. 14, [27] [28] [29] Although this PKC is ubiquitously expressed, the mice that do not express PKC␦ show a clear phenotype only in immune cells. 14 Indomethacin-treated platelets from PKC␦ Ϫ/Ϫ mice and their age-matched wild-type littermate controls were stimulated with submaximal doses of AYPGKF (200 mol/ L), or GPVI agonists-convulxin (60 ng/mL), collagen-related peptide (CRP, 5 g/mL), or collagen (20 g/mL). Platelet aggregations and dense granule secretions were measured in these platelets on agonist stimulation. As shown in Figure 2A , aggregations and dense granule secretions were inhibited on stimulation with AYPGKF in PKCd Ϫ/Ϫ murine platelets compared to wild-type littermates. On the other hand, secretion induced by GPVI agonists were potentiated. These results are consistent with the findings using (␦ V1-1) TAT in human platelets. Dense granule secretions were also measured in the absence of indomethacin and inhibition or potentiation was found to be statistically significant ( Figure 2B ). The actual ATP released in nmoles was quantitated and the inhibition or potentiation were statistically significant (Figure 2A and  2B) . These data suggest that PKC␦ differentially regulates PARs and GPVI-mediated dense granule secretions in murine platelets.
PKC␦ Regulates PAR and GPVI-Mediated ␣-Granule Secretion
The exposure of P-selectin from ␣-granules aids in different cell-cell interaction between platelets, leukocytes, and endothelial cells. 11, 30 As PKC␦ differentially regulates dense granule secretion, we investigated the role of this isoform in ␣-granule secretion. Washed indomethacin-treated murine platelets from PKC␦ Ϫ/Ϫ and wild-type littermates were stimulated with submaximal doses of AYPGKF or convulxin and P-selectin exposure was measured by flow cytometry. Our results showed that PAR-mediated ␣-granule secretion, expressed as Mean Fluoroscence Intensity (MFI), was inhibited and GPVI-mediated ␣-granule secretion was potentiated marginally in PKC␦ Ϫ/Ϫ compared to wild-type littermates (Figure 3) . These results indicate that PKC␦ plays a differential role in regulating ␣-granule secretion downstream of PARs and GPVI receptors.
Role of PKC␦ in PAR and GPVI-Mediated Thromboxane A 2 Generation
We have previously shown, using rottlerin, that PKC␦ regulates PAR-mediated thromboxane A 2 (TXA 2 ) genera-tion. 31 Therefore, we next investigated the contribution of PKC␦ to TXA 2 generation downstream of PARs and GPVI receptors using platelets from PKC␦-null mice. PARmediated TXA 2 generated was inhibited in PKC␦ Ϫ/Ϫ murine platelets compared to the wild-type littermates ( Figure 4A ). On the other hand, GPVI-mediated TXA 2 generated was potentiated in PKC␦ Ϫ/Ϫ murine platelets compared to the wild-type littermates ( Figure 4B ). These statistically significant results (PϽ0.05) suggest that PKC␦ positively regulates PAR-mediated TXA 2 genera- (Figure 4 ). All experiments were repeated 4 times using platelets from both mice (nϭ4). The data were represented as MFI and analyzed using Student t test, and PՅ0.05 was considered significant. 
PKC␦ Plays a Role in Regulating PKC-Dependent Fibrinogen Receptor Activation
Calcium and PKC pathways can independently cause PAR and GPVI-mediated fibrinogen receptor activation. 12 To investigate the role of PKC␦ in PKC-dependent fibrinogen receptor activation, washed aspirin-treated human platelets were pretreated with dimethyl BAPTA (10 mol/L) for 5 minutes, which completely blocks the calcium-dependent pathways. We confirmed the effectiveness of BAPTA by measuring secretion on stimulation with AYPGKF, which was abolished. These BAPTA-treated platelets were then preincubated with (␦ V1-1)TAT or control peptide for 10 minutes, stimulated with submaximal doses of PAR4 agonist peptide, AYPGKF (200 mol/L) in the presence of fibrinogen (1 mg/mL). This resulted in the inhibition of AYPGKFinduced aggregation, whereas the control peptide had no effect ( Figure 5A) . Similarly, when indomethacin-treated PKC␦ Ϫ/Ϫ and wild-type platelets were preincubated with BAPTA for 5 minutes, AYPGKF-induced (200 mol/L), aggregation was inhibited ( Figure 5B ). These results indicate that PKC␦ is one of the isoforms contributing to PKCdependent platelet aggregation. However, as the aggregation was not abolished in the case of pan-PKC inhibitors, 12 suggesting that other PKC isoforms might also be contributing to this event.
Regulation of Thrombus Formation by PKC␦ In Vivo
We investigated whether the results using ex vivo platelets translate into an in vivo aberration in thrombus formation in mice. 32 Hence, we evaluated the role of PKC␦ in thrombus formation in vivo using FeCl 3 -induced carotid artery injury model. As shown in Figure 6A and 6B, the time to occlusion (TTO) in a representative wild-type and PKC␦ Ϫ/Ϫ mice were 6.5 minutes and 4 minutes, respectively. However, the time to occlusion of wild-type (12.85Ϯ11.13 minutes) and PKC␦ Ϫ/Ϫ (7.94Ϯ7.56 minutes) shown in Figure 6C (nϭ11) indicate that the differences in times to occlusion are not statistically significant (PϾ0.1) as judged by Student t test. These results indicate that PKC␦ deficiency does not affect the thrombus formation in vivo.
Discussion
Previously, differential regulation of dense granule secretion by PKC␦ isoform downstream of PAR and GPVI receptors was studied using rottlerin. 15 However, recent reports have indicated problems regarding the specificity of rottlerin as a PKC␦ inhibitor. 18 -20 It inhibits other protein kinases such as MAPK-activated protein kinase 2 and p38 regulated/activated kinase, and other enzymes such as ␤-lactamase, chymotrypsin, and malate dehydrogenase. 18 -20 To substantiate the previous findings with rottlerin, we used 2 complementary approaches in the current study. The first approach is the pharmacological approach, using (␦ V1-1)TAT, an anti-PKC␦ RACK peptide, and the second approach, extending the pharmacological findings, is the use of mice lacking PKC␦.
For the pharmacological inhibition of PKC␦, (␦ V1-1)TAT was used. The specificity of the (␦ V1-1)TAT peptide has been well established by previous studies, 6, 26, 33 wherein the anti-PKC␦ RACK peptide was shown to inhibit the translocation of PKC␦ but not PKC␣, ␤I, . Furthermore, in platelets, 2MeSADP does not activate PKC␦. 15 2MeSADPinduced aggregations were not affected in human platelets that were pretreated with anti-PKC␦ RACK peptide suggesting that this peptide is specific for PKC␦ isoform (data not shown). Our results using (␦ V1-1)TAT in human platelets and platelets from mice lacking PKC␦ showed inhibition of PAR-mediated and potentiation of GPVI-mediated platelet dense granule secretions and TXA 2 generation. The effects of PKC␦ were statistically significant only at submaximal doses of the agonist and not at higher doses (data not shown). Thus, PKC␦ differentially regulates dense granule secretion and thromboxane generation in platelets downstream of PARs and GPVI.
Previous findings from Pula et al 34 reported that PKC␦ does not play any significant role in GPVI-mediated dense granule secretion and fibrinogen binding. Our results are in contrast with these findings, because we observed a negative regulatory role for this PKC isoform downstream of GPVI in this study. There are plausible explanations for these differ- Figure 5 . PKC␦ contributes to PKCdependent pathway of PAR4-mediated fibrinogen receptor activation. Washed aspirin-treated human platelets were preincubated with (␦ V1-1)TAT or the control peptide for 10 minutes followed by incubation with 10 mol/L BAPTA for 5 minutes, stimulated with 200 mol/L AYPGKF (PAR-4 agonist peptide) and 1 mg/mL fibrinogen for 3 minutes under stirring conditions at 37°C. B, Washed indomethacin-treated murine platelets from PKC␦ Ϫ/Ϫ and wild-type littermates were preincubated with 10 mol/L BAPTA for 5 minutes, stimulated with 200 mol/L AYPGKF in the presence of 1 mg/mL fibrinogen, and the aggregations and dense granule secretions were recorded in a Lumi-aggregometer. ences in the results. Previous studies in the PKC␦ Ϫ/Ϫ were carried out using a very low concentration of 3 g/mL collagen to measure the release of 5-HT as a marker for dense granule secretion. At low doses of collagen, the effects are mostly dependent on feedback mediators such as ADP and TXA 2 . Although, ADP was scavenged using 0.2 U/mL apyrase, the effects that were reported may be mediated by TXA 2 , because dense granule secretions were measured in the absence of indomethacin. Therefore, under such low collagen concentrations, the role of PKC␦ in dense granule secretion cannot be observed. Moreover, dense granule secretions were measured using serotonin assay (5-HT assay) where radioactive 14 C is used. In this case, the platelet response cannot be monitored continuously. In our ATP secretion assay, we monitored both aggregation and secretion continuously and hence observed the differences in the responses. Moreover, we strengthened our findings using other GPVI receptor agonists like CRP and convulxin in addition to collagen. Therefore, these discrepancies seen between our data and data from Pula et al could be attributed to different experimental approaches. 34 Such discrepancies have been noted in the case of other studies using the same knock-out mice strains. For example, results from SHIP-1 Ϫ/Ϫ murine platelets by Severin et al 35 and Pasquet et al 36 are contradictory. Although both the groups used mice of the same strain, there were differences in the experimental results. These may be attributed to the differences in experimental methodology.
After platelet secretion, TXA 2 is generated which amplifies the platelet functional responses. Previous reports indicated a role for PKC␦ in regulating PAR-mediated TXA 2 generation, 31 but its role downstream of GPVI receptors is not known. Our current data suggest that PKC␦ positively regulates AYPGKF-induced TXA 2 generation and negatively regulates GPVI-mediated TXA 2 generation. The enhanced platelet functional responses, viz secretion and thromboxane generation, downstream of GPVI stimulation in PKC␦ null mice, however, did not translate into statistically significant difference in the time to occlusion of the ferric chlorideinjured artery in these mice.
We have previously shown that PAR-mediated platelet aggregation occurs in a calcium-and PKC-dependent manner. 12 Here, we show that PKC␦ contributes to the PKCdependent platelet aggregation by AYPGKF. As pan-PKC isoforms completely abolish PKC-dependent aggregation 12 but this aggregation was only partially blocked by PKC␦ antagonistic RACK peptides or in PKC␦ null murine platelets. These results suggest that other PKC isoforms might contribute to the PKC-dependent aggregation. Previous studies have shown that BAPTA treatment enhances the membrane translocation of the PKC isoform. 37 Thus, it is possible that the PKC isoform might be more activated and take over the function of PKC␦ in BAPTA-treated platelets.
Signaling through PARs involves G-protein signaling pathways, unlike GPVI receptor signaling that is mediated by tyrosine kinases. Therefore, the downstream signaling molecules are different in PAR and GPVI-signaling pathways. PAR-mediated signaling involves PLC␤ 2, whereas the key signaling molecule in GPVI signaling is, PLC␥ 2 . These signaling molecules upstream of PKC␦ may differentially regulate PKC␦ and result in the differential regulation of platelet functional responses. However, the molecular mechanism of such differential regulation is not clear. Recent reports have indicated Rab27b (a Rab27 GTPase subfamily) and Ral (a GTPase) to regulate platelet dense granule secretion. 38, 39 It is possible that PKC␦ may regulate small G proteins, which aid in the fusion of t-SNAREs and v-SNAREs, differentially downstream of PAR and GPVI-mediated platelet exocytosis. Future studies have to address the mechanism of such differential regulation by this PKC isoform.
In conclusion, PKC␦ differentially contributes to the regulation of PAR-and GPVI-mediated secretion and TXA 2 generation. However, the altered platelet functional responses in PKC␦ null mouse platelets do not affect thrombus formation in the injured artery in these mice. 
